(external) researcher Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- westgeest@eshpm.eur.nl
More information
‹ Back to overview
Profile
- K. de Joode, D.W. Dumoulin, J. Tol, H.M. Westgeest, L. Beerepoot, F.W.P. van den Berkmortel, P.G.N.J. Mutsaers, N.G.J. van Diemen, O.J. Visser, E. Oomen-de Hoop, H. Bloemendal, H. van Laarhoven, L.E.L. Hendriks, J. Haanen, E.G. de Vries, A.C. Dingemans, A.A.M. van der Veldt, C.J. van Loenhout, C.H. van der Leest, A. Becker-Commissaris, J.S.W. Borgers, F. Terhegggen, B. van den Borne, L.J.C. van Warmerdam, L. van Leeuwen, F.S. van der Meer, M.A. Tiemessen, D.M. van Diepen, Y. Klaver, A.P. Hamberg, E.J. Libourel, L. Strobbe, M. Cloos, E.J. Geraedts, JC Drooger, R. Heller, J.W.H. de Groot, J. Stigt, V.J.A.A. Nuij, C.C.M. Pitz, M. Slingerland, F.J. Borm, B.C.M. Haberkorn, S.C.V. Westeinde, M. Aarts, J.W.G. van Putten, M. Youssef, G. Cirkel, G.J. Herder, C.R. van Rooijen, E. Citgez, N.P. Barlo, B.M.J. Scholtes, R.H. Koornstra, N.J.M. Claessens, L. Faber, C.H. Rikers, R.A.W. van de Wetering, G.L. Veurink, B.W. Bouter, I. Houtenbos, M.P.L. Bard, K.H. Herbschleb, E.A. Kastelijn, P. Brocken, G. Douma, M. Jalving, T.J.N. Hiltermann, O.C.J. Schuurbiers-Siebers, K. Suijkerbuijk, A.S.R. van Lindert, A.J.V. de Wouw, V.E.M. van den Boogaart, S.D. Bakker, E. Looysen, A.L. Peerdeman, W.K. de Jong, E.J.M. Siemerink, A.J. Staal, B. Franken, W.H. van Geffen & G.P. Bootsma (2020). Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer, 141, 171-184. doi: 10.1016/j.ejca.2020.09.027
- H.M. Westgeest, M.C.P. Kuppen, A.J.M. Van den Eertwegh, R. de Wit, J. Coenen, H. van den Berg, N. Mehra, I. van Oort, L. Fossion, M.P. Hendriks, H. Bloemendal, A.C.M. van de Luijtgaarden, D. Huinink, A.C.M. van den Bergh, J.G. Bosch, M.B. Polee, N. Weijl, A. Bergman, C.A. de Groot & W. Gerritsen (2019). Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical Genitourinary Cancer, 17 (5), E946-E956. doi: 10.1016/j.clgc.2019.05.018
- M.C.P. Kuppen & H.M. Westgeest (2019). Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Oncology. doi: 10.1016/j.euo.2019.09.005.
- H.M. Westgeest, C.A. de Uyl-de Groot, R.J.A. van Moorselaar, R. de Wit, A.C.M. van den Bergh, J.L.L.M. Coenen, H.P. Beerlage, M.P. Hendriks, M. Bos, P. van den Berg, A. van de Wouw, T. Spermon, M.O. Boerma, M.M. Geenen, L.W. Tick, M.B. Polee, H. Bloemendal, I. Cordia, F.P.J. Peters, A.I. de Vos, J. van den van den Bosch, A.J.M. Van den Eertwegh & W. Gerritsen (2018). Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology, 4 (5), 694-701. doi: 10.1016/j.euf.2016.09.008
- S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007
(external) researcher
- University
- Erasmus University Rotterdam
- School
- Erasmus School of Health Policy & Management
- Department
- Health Technology Assessment (HTA)
- Country
- The Netherlands